May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
In vitro study of corneal retention of Cyclosporine–A from different formulations
Author Affiliations & Notes
  • J.D. Quintana–Hau
    Research and Development,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • E. Cruz–Olmos
    Research and Development,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • M.I. Lopez–Sanchez
    Research and Development,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • J.R. Gonzalez
    Medical Department,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • L. Baiza–Duran
    Medical Department,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • V. Sanchez–Castellanos
    Medical Department,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • R. Tornero–Montaño
    Medical Department,
    Laboratorios Sophia SA de CV, Guadalajara, Mexico
  • Footnotes
    Commercial Relationships  J.D. Quintana–Hau, Laboratorios Sophia SA de CV E; E. Cruz–Olmos, Laboratorios Sophia SA de CV E; M.I. Lopez–Sanchez, Laboratorios Sophia SA de CV E; J.R. Gonzalez, Laboratorios Sophia SA de CV E; L. Baiza–Duran, Laboratorios Sophia SA de CV E; V. Sanchez–Castellanos, Laboratorios Sophia SA de CV E; R. Tornero–Montaño, Laboratorios Sophia SA de CV E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 67. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.D. Quintana–Hau, E. Cruz–Olmos, M.I. Lopez–Sanchez, J.R. Gonzalez, L. Baiza–Duran, V. Sanchez–Castellanos, R. Tornero–Montaño; In vitro study of corneal retention of Cyclosporine–A from different formulations . Invest. Ophthalmol. Vis. Sci. 2004;45(13):67.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Compare the amount of Cyclosporine–A (CsA) retained in cornea after its topical application under different formulations. Methods: It was compared MODUSIK–A OftenoTM (0.05% and 0.1%) against the RestasisTM (0.05% CsA in castor oil; Allergan, Irvine CA) and MODUSIK–A OftenoTM (0.1%) against 2.0% CsA in olive oil as vehicle. Corneal passive diffusion was evaluated using a side–by–side chamber (Crow Glass Co., Somerville NJ) separated by a fresh cornea from New Zealand white rabbits. Corneal epithelium faced the donor chamber and endothelium faced the receptor chamber. CsA was extracted from the tissue using methanol, and its concentration was determined by HPLC. Results: The total amount of CsA was comparable when 0.05% MODUSIK–A OftenoTM and RestasisTM were used as donors (3.52 µg±1.87 versus 3.61 µg±2.61), but a slight increase of was observed when 0.1% MODUSIK–A OftenoTM was compared to RestasisTM. Also, no differences of CsA amount in cornea was observed when 0.1% MODUSIK–A OftenoTM and 2.0% CsA in olive oil were challenged as donors. Conclusions: These results suggest that 0.05%, 0.1% MODUSIK–A OftenoTM and RestasisTM worked very similar in terms of passive diffusion in cornea. This suggested than MODUSIK–A OftenoTM is a proper aqueous formulation to deliver CsA to the eye. Using 2.0% CsA in olive oil as donor do not improve the corneal CsA amount when it was compare to 0.1% MODUSIK–A OftenoTM. This indicates that cornea has limited passive diffusion capacity for CsA.

Keywords: cyclosporine • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×